Compare Nasdaq Inc (NDAQ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Tango Therapeutics Inc. — how do they compare? Nasdaq Inc trades at $91.96 (market cap $52.25B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Nasdaq Inc is far larger — about 13.9× Tango Therapeutics Inc.'s market cap, and Nasdaq Inc pays a 1.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Tango Therapeutics Inc. for 0 Days on average.
| NDAQ | TNGX | |
|---|---|---|
Market Cap | $52.25B | $3.75B |
Volume | 2,420,834 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $100.98 | $32.90 |
52-Week Low | $76.85 | $7.50 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $58.71B | $2.77B |
Dividend Yield | 1.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $91.96, down 2.47% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with 2025 revenue of $8.26B and net income of $1.79B, achieving a 21.64% profit margin. Recent earnings beats and analyst consensus of $110.43 price target reflect confidence in growth driven by financial technology and AI initiatives.
NDAQ presents a compelling investment case with solid profitability and strategic positioning in market infrastructure. Key risks include market volatility sensitivity and debt levels, but strong cash flow and institutional support provide stability. The stock offers upside potential aligned with analyst targets, supported by recurring revenue growth and technology adoption.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
